|
On Tuesday, October 3, the FDA authorized under EUA the Novavax monovalent XBB.1.5 COVID-19 vaccine for persons aged 12 and older for 2023–2024 COVID-19 season. The Novavax COVID-19 Vaccine, Adjuvanted (Original monovalent) is no longer authorized for use in the United States. Read the FDA's statement. The FDA also offers Novavax Fact Sheets in English, Chinese, Korean, Spanish, Tagalog and Vietnamese.
Pneumococcal Vaccine Recommendations Made Easy
The CDC recently updated Pneumococcal Vaccine recommendations for Adults aged >19 years. The Advisory Committee on Immunization Practices (ACIP) recommendations specify the use of either PCV20 alone or PCV15 in series with PPSV23 for all adults aged ≥65 years and for adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not received a PCV or whose vaccination history is unknown. In addition, ACIP recommends use of either a single dose of PCV20 or ≥1 dose of PPSV23 for adults who have started their pneumococcal vaccine series with PCV13 but have not received all recommended PPSV23 doses. Shared clinical decision-making is recommended regarding use of a supplemental PCV20 dose for adults aged ≥65 years who have completed their recommended vaccine series with both PCV13 and PPSV23.
Download the PneumoRecs Vax Advisor App to help you quickly and easily determine which pneumococcal vaccines a patient needs and when. IPRO also has many updated vaccine resources. Download the IPRO LINKS Immunization Portfolio that includes an Adult Immunization Record to help adults keep track of the vaccines they have received.
| 
